With our deep expertise in liver immunology, Ace Therapeutics is committed to providing support for the development of next-generation hepatitis vaccines by applying antigen engineering technologies and delivery platforms to overcome the limitations of current clinical applications.
Types of Hepatitis Virus Vaccines
Cutting-edge vaccine technologies include virus-like particles (VLPs), mRNA platforms, and adenoviral vector systems, which are transforming hepatitis prophylaxis through two key approaches: enhancing existing vaccine formulations and enabling novel multivalent vaccine development. These advanced modalities offer distinct immunological advantages for combating hepatitis viruses A through E, as evidenced by recent clinical breakthroughs in immunogenicity and cross-protection.
|
Current States |
R & D Advances |
| Hepatitis A (HAV) Vaccines |
- Inactivated vaccines (e.g., Havrix, Vaqta)
|
- Oral live-attenuated vaccines (e.g., China's H2 strain) in development for cost-effective use in endemic regions.
- Combination vaccines (e.g., HAV-HBV) to simplify immunization schedules.
|
| Hepatitis B (HBV) Vaccines |
- Recombinant protein vaccines (e.g., Engerix-B, Recombivax HB)
- Adjuvanted vaccine (Heplisav-B)
|
- mRNA vaccines: Phase II trials for prophylactic and therapeutic use.
- Therapeutic vaccines: Viral vectors (ChAdOx1-HBV), DNA vaccines, and checkpoint inhibitor combos to cure chronic HBV.
|
| Hepatitis C (HCV) Vaccines |
- No approved vaccine; direct-acting antivirals (DAAs) cure >95% of infections.
|
- T-cell vaccines (e.g., ChAd3/MVA-vectored NS3/4 antigens) to prevent chronic infection.
- mRNA vaccines targeting conserved E2 glycoprotein epitopes.
- B-cell epitope vaccines to induce broadly neutralizing antibodies.
|
| Hepatitis D (HDV) Vaccines |
- No HDV-specific vaccine; HBV vaccination prevents HDV coinfection.
|
- HDV antigen-based vaccines (e.g., recombinant HDAg) in preclinical studies.
- Gene-silencing therapies (e.g., siRNA) paired with HBV functional cures.
|
| Hepatitis E (HEV) Vaccines |
- Recombinant protein vaccine
|
- pORF2-based VLP vaccines to improve thermostability.
- Combination vaccines (e.g., HAV-HEV) for travelers and endemic regions.
|
Types of Hepatitis Virus Vaccine We Can Develop
- mRNA Vaccines for HBV/HCV
Leveraging cutting-edge mRNA platform technology, we support the development of next-generation hepatitis vaccines targeting conserved viral epitopes (including HBV Pre-S/S and HCV E2 domains) to elicit potent and durable humoral and cellular immune responses. Our approach combines rapid antigen design capabilities with advanced lipid nanoparticle delivery systems, enabling both preventive vaccination and therapeutic applications against hepatitis viral infections.
- Therapeutic Vaccines for Chronic HBV Infection
Our therapeutic vaccine development strategy for chronic HBV infection focuses on overcoming immune tolerance through multi-antigen platforms incorporating both structural (HBsAg) and core (HBcAg) viral proteins, delivered via advanced DNA vaccine or viral vector systems. These constructs are further enhanced with strategic immunomodulatory components including checkpoint inhibitors and cytokine adjuvants, designed to restore functional antiviral immunity and achieve sustained viral control in persistently infected individuals.
- Multivalent Antigen Vaccines
To overcome the challenge of HBV/HCV genetic diversity, our vaccine design strategy employs multivalent antigen constructs combining both structural domains (including HBV Pre-S1, Pre-S2, and S proteins) and highly conserved nonstructural elements (such as HCV NS3/4A protease). This innovative approach significantly broadens immunogen coverage across viral genotypes while enhancing cross-neutralizing antibody responses and T-cell recognition, providing comprehensive protection against diverse viral quasispecies.
- VLP (Virus-Like Particle) Vaccines
Our VLP technology platform mimics native viral architectures through spontaneous self-assembly of structural antigens (including HBV surface proteins), creating highly immunogenic particulate vaccines that enhance both antigen presentation and immune recognition. These versatile VLP platforms enable the development of multivalent combination vaccines (HAV-HBV-HEV) while demonstrating exceptional thermal stability for cold-chain-independent distribution in resource-limited settings.
- Mucosal Vaccines for HAV/HEV
We can utilize engineered adenoviral vectors delivered via oral or intranasal routes to elicit robust gut-associated lymphoid tissue immunity, specifically targeting the primary entry points for HAV/HEV fecal-oral transmission. These formulations incorporate advanced enteric protection technologies including pH-responsive polymer coatings and lipid-polymer hybrid nanoparticles to ensure optimal antigen delivery across the gastrointestinal mucosa while protecting against premature degradation.
Ace Therapeutics is at the forefront of innovative hepatitis vaccine development, addressing critical unmet needs in immunogenicity, administration routes, and population coverage through cutting-edge mRNA platforms, therapeutic vaccine approaches, and multivalent antigen designs. If you'd like to prioritize specific areas, please do not hesitate to contact us.
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
